Cancer Research

Papers
(The H4-Index of Cancer Research is 66. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Abstract P5-13-17: PD-L1 expression in breast to brain metastases668
Abstract GS2-01: Overall survival subgroup analysis by metastatic site from the phase 3 MONALEESA-2 study of first-line ribociclib + letrozole in postmenopausal patients with advanced HR+/HER2− breast231
Abstract PD4-03: Characterization of HER2 amplification in the cerebrospinal fluid of patients with Leptomeningeal Disease in stage IV patients with breast cancer211
Abstract P1-13-04: Evaluation of the impact Vitamin D and Calcium supplementation on bone mineral density in breast cancer patients using or not taking Aromatase Inhibitors: 5-year follow-up191
Abstract OT1-05-01: Glycoprotein 88 (GP-88) serum levels as a marker of response to therapy in patients with metastatic breast cancer172
Abstract P3-19-16: Impact of targeted intraoperative (TARGIT-IORT) tumor bed boost during breast conserving surgery for early breast cancer on breast cancer associated and non-breast cancer associated150
Abstract P2-12-23: Changes in 18F-FDG-PET uptake after the first course of DTX reflect response to preoperative chemotherapy and prognosis in breast cancer150
Abstract P4-12-09: Implications of protocol modifications and treatment delays for breast cancer patient experiences during Covid-19143
Abstract P3-20-09: Surgery vs radiation therapy as the first stage treatment in patients with locally advanced breast cancer with incomplete clinical response142
Abstract PD3-03: EZH2 T367 phosphorylation activates p38 signaling through lysine methylation to promote breast cancer progression142
Abstract P4-01-16: Overcome chemoresistance of triple-negative breast cancer by inhibiting the RNA-binding protein HuR128
Abstract OT2-21-01: A randomized, multicenter pragmatic trial comparing bone pain from a single dose of pegfilgrastim to 5 doses of daily filgrastim in breast cancer patients receiving neoadjuvant/adj125
Abstract P4-11-16: Feasibility and patient satisfaction with a smartphone application to improve medication adherence among patients with breast cancer125
Abstract P3-12-20: Outcomes of patients with pathologic complete response following neoadjuvant HER2-targeted therapy in patients with HER2+ early stage breast cancer120
Abstract P1-08-07: Prediction model of the response of neoadjuvant chemotherapy and long term survival according to multi-omic profiling in cooperation with clinicopathologic features in patients with117
Abstract P1-06-01: Insights from rapid autopsy shed light on mechanisms of cancer dissemination in metastatic breast cancer104
Abstract P3-18-14: Assessment of quality of life and objective cosmetic outcome of breast conserving surgery with or without latissimus dorsi mini-flap in breast cancer103
Abstract P4-11-05: How to stay sexually active and sexually well-functioning after breast cancer - Reporting from the SWEET study103
Abstract P4-05-09: Clinicopathologic characteristics and molecular profiling of HER2-low breast cancer: A single academic institution experience99
Abstract ES8-2: Can radiation replace ALND after positive SLNB?96
Abstract P5-14-10: Examining inequities associated with incarceration among patients with breast cancer95
Abstract P1-07-01: Real time detection of ESR1 mutation in blood by droplet digital PCR in the PADA-1 trial: Feasibility and cross-validation with NGS93
Editor's Note: p38 Mitogen-Activated Protein Kinase-Driven MAPKAPK2 Regulates Invasion of Bladder Cancer by Modulation of MMP-2 and MMP-9 Activity92
Abstract P1-08-09: High mid-treatment RNA disruption in patients with HER2-negative breast cancer predicts survival benefit after neoadjuvant chemotherapy92
Abstract P2-15-01: Conversion from luminal to normal intrinsic subtype by PAM50 after neoadjuvant endocrine therapy is associate with biomarkers of good prognosis in luminal breast cancer90
Abstract P1-18-17: Phase I study of cfi-402257, an oral ttk inhibitor, in patients with advanced solid tumors with breast cancer expansion cohorts89
Hyperactive Dendritc Cells Redirect Aged Antitumor Immunity89
Abstract P5-08-02: MORAb-202, an antibody-drug-conjugate (ADC) targeting folate receptor alpha (FRα), exhibits durable anti-tumor efficacy in PDx models of TNBC88
Abstract A068: A phase 2 study to investigate the efficacy and safety of acoustic cluster therapy with modified FOLFIRINOX in patients with locally advanced pancreatic cancer88
Abstract A117: Co-priming sonic hedgehog inhibitor sonidegib with plerixafor induces tumor microenvironment transformation that enhances fluorescent nanoparticle deposition in pancreatic tumor xenogra86
Abstract A035: KMT2D Loss Induces Enrichment of Plod2+ Fibroblasts in Pancreatic Cancer85
Abstract A027: HuR drives immune evasion, metastases and KRAS addiction in pancreatic ductal adenocarcinoma: implications for IO-based and KRAS inhibitor therapies84
Abstract P5-01-03: Mouse-intraductal (MIND): An in vivo model for studying the underlying mechanisms of DCIS malignancy84
Abstract P4-10-10: Effectiveness and feasibility of exercise-oncology programs in breast cancer patients using new technologies adapted to the COVID 19 new normality84
Abstract 7004: CT7439 an oral first-in class selective CDK12 and 13 inhibitor and cyclin K degrader: Profiling activity and combination efficacy in an ovarian cancer model82
Cancer Research in the Age of Big Data81
Neuroblastoma Differentiation: The Untapped Potential of Mitochondrial Uncouplers81
Abstract CT247: FORTE: A phase 2 master protocol assessing plixorafenib for BRAF-altered cancers80
Abstract 6922: MDM2 inhibitor alrizomadlin induces ferroptosis through p53 dependent and independent pathways in TP53 wildtype NSCLC80
Abstract P84: Sorted cell populations with epigenetically silenced chromosomally dispersed reporter fluorophore gene as a test-system for the screening of non-genotoxic carcinogens77
Abstract IA002: Full circle: Return of value to ovarian cancer research participants, advocates, and survivors77
Abstract LB129: VTS105: A novel and potent BCMA/GPRC5D/CD3 trispecific T cell engager (TCE) for the treatment of hematologic malignancies and autoimmune diseases77
Abstract IA025: AI-powered discovery of biomarkers from histopathological images in ovarian cancer76
Abstract B058: VEGF inhibition enhances immune checkpoint blockade efficacy in ovarian cancer75
Abstract A051: Targeting notch signaling pathway with auranofin for endometrial cancer therapy75
Abstract PR004: Phase 2 study of the PD-L1 inhibitor durvalumab and VEGFR inhibitor cediranib combination with and without PARP inhibitor olaparib in patients with recurrent ovarian cancer75
Abstract A029: PARP-targeted alpha therapy for the treatment of PARP inhibitor resistant ovarian cancer74
The Approaching Darwinian Era in Oncology73
Abstract B039: Application of unsupervised clustering to whole slide images of high-grade serous ovarian cancer predicts prognosis73
Abstract P51: MCL-1 safeguards activated hair follicle stem cells to enable adult hair regeneration71
Abstract P30: Targeting B7-H3 Positive Solid Tumor Malignancies with Chimeric Antigen Receptor Epstein-Barr Virus Specific T Cells Armoured with An Engineered SerpinB9 Molecule for Improved Persistenc71
Abstract P4-12-14: Assessing patients perceptions on hormone therapy for breast cancer: Insights from a Brazilian patient group70
Abstract P56: Suppression of Breast Cancer Growth via Inhibition of c-Myc Expression by RUNX370
Abstract A050: Truncated PPM1D cooperates with the PI3K pathway to drive Diffuse Midline Gliomas70
Abstract PD13-07: Activity and biomarker analyses from a phase Ia/b study of giredestrant (GDC-9545; G) with or without palbociclib (palbo) in patients with estrogen receptor-positive, HER2-negative l70
Abstract 4286: CHK1 as a novel therapeutic target for pleural mesothelioma69
Abstract B031: Uncovering genetic and regulatory drivers of tumor-specific splicing in pediatric brain tumors69
Abstract 3358: Tertiary lymphoid structures (TLS) estimated by AI tools from digital H&E slides significantly enhance survival prediction in high-risk AJCC stages III/IV melanoma69
Abstract A002-PR011: Precision Diagnosis in High-Risk Pediatric Oncology through Integrated Whole Genome, Transcriptome, and Epigenome Profiling69
Blocking Nitrosylation Induces Immunogenic Cell Death by Sensitizing NRAS -Mutant Melanoma to MEK Inhibitors68
Editor’s Note: A Novel Role for Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6 as a Determinant of Gemcitabine Chemoresistance in Pancreatic Adenocarcinoma Cells67
Abstract 524: An integrative approach to unveiling biomarkers and therapeutic targets identifies novel treatment strategy for advanced prostate cancer67
Abstract 352: Preclinical development of MHB042C: A next-generation anti-c-Met ADC conjugating VHH-Fc fusion protein with a novel topoisomerase I inhibitor67
Abstract 817: A prospective, multi-center, phase IV study to evaluate safety and efficacy of Dr. Reddy’s bevacizumab (DRL_BZ) in patients with solid tumors66
Abstract 515: Repurposing nebivolol with dasatinib and CPI-613: A synergistic strategy to combat triple-negative breast cancer66
Abstract 115: S-adenosyl-methionine (SAM) synthesis protects ovarian cancer from chemotherapy induced DNA damage and contributes to cancer stem cell enrichment66
0.25919485092163